Eosinophilia NSCLC Treatment Immune Adverse Events
Summary of Research on Eosinophilia and NSCLC Treatment with ICIs
This research review investigated the relationship between pretreatment eosinophil levels and outcomes in patients with Non-Small Cell lung Cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICIs). Here’s a breakdown of the key findings:
Methods:
* Data Sources: PubMed, ScienceDirect, PMC, web of Science, Google Scholar, and Cochrane Library were searched.
* Study Inclusion: Included studies focused on adult NSCLC patients (18+ years) with reported pretreatment eosinophil levels.
* Study Exclusion: Reviews, conference abstracts, animal studies, non-English articles, case reports, and studies lacking sufficient data or separating NSCLC from other cancers were excluded.
* Data Extraction: Researchers collected sociodemographic data, study details, and outcomes.
Key Findings:
* Study Characteristics: The review included 11 retrospective cohort studies from North America, Europe, and Asia, encompassing 14,095 patients.
* Overall Survival (OS): No significant association was found between pretreatment eosinophilia and overall survival, either unadjusted (OR 0.79) or adjusted (OR 0.74).
* Progression-Free Survival (PFS): While an initial unadjusted analysis showed a trend towards reduced PFS with higher eosinophil levels, this was not significant. After adjustment, a significant association emerged, indicating that eosinophilia was linked to lower odds of longer PFS (OR 0.68).
* Immune-Related Adverse Effects (irAEs): Patients with pretreatment eosinophilia had a significantly increased risk of irAEs, both unadjusted (OR 3.19) and adjusted (OR 3.35).
Limitations:
* observational Studies: All studies were observational, potentially introducing selection bias.
* Retrospective Design: The retrospective nature of the studies prevents drawing causal conclusions.
* Heterogeneity in Eosinophilia Definition: Variations in how eosinophilia was defined across studies could have impacted results.
* Inconsistent Follow-up Reporting: Inconsistent reporting of follow-up duration was noted.
* OR vs. HR: Using Odds Ratios (OR) instead of Hazard ratios (HR) may not fully capture survival dynamics.
in essence, the review suggests that while eosinophilia doesn’t appear to impact overall survival, it is associated with shorter progression-free survival and a significantly higher risk of immune-related side effects in NSCLC patients treated with ICIs.